Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases
- PMID: 36008876
- DOI: 10.1111/his.14783
Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases
Abstract
Separation of mesothelioma from metastatic carcinoma requires immunohistochemical support, with small batteries of stains recommended as a starting-point, but these numbers commonly expand to 10, 12 or more stains, a process that is not only expensive but frequently generates anomalous or confounding results, leading to even more stains. Here we review data on HEG1 clone SKM9-2, a new (now commercially available) mesothelioma marker and claudin-4, a broad-spectrum carcinoma marker, to ask whether these two stains are sufficient, by themselves, to separate mesotheliomas from non-small-cell lung (NSCLC) as well as other carcinomas. Data for HEG1, derived from four laboratories, showed membrane staining in 393 of 434 (91%) epithelioid/biphasic mesotheliomas and one of 360 (0.3%) NSCLC (sensitivity 91%, specificity 99.7%). Reports from seven laboratories evaluating claudin-4 in NSCLC showed positivity in 469 of 502 (93%) carcinomas and weak positivity in five of 463 (1.0%) epithelioid/biphasic mesotheliomas (sensitivity 93%, specificity 98.9%). Comparable results were found with carcinomas from other sites, except for serous and thyroid carcinomas, some of which react with HEG1 but are also positive for claudin-4. For sarcomatoid mesotheliomas, HEG1 sensitivity is modest and staining sometimes difficult to interpret. We hypothesise that the combination of HEG1 and claudin-4 immunostaining will potentially allow the separation of epithelioid/biphasic mesotheliomas from NSCLC carcinomas with high accuracy using only two immunostains in most cases. This combination will probably also work for carcinomas from most other sites, but more reports on HEG1 SKM9-2 staining of carcinomas other than NSCLC are needed. This approach would greatly simplify the diagnosis of mesothelioma.
Keywords: HEG1; claudin-4; mesothelioma; non-small-cell lung carcinoma.
© 2022 John Wiley & Sons Ltd.
Similar articles
-
Mesothelioma: morphologic and immunohistochemical findings.Pathologie (Heidelb). 2024 Sep;45(5):309-315. doi: 10.1007/s00292-024-01317-6. Epub 2024 Apr 3. Pathologie (Heidelb). 2024. PMID: 38568257 Review. English.
-
HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.Am J Surg Pathol. 2020 Aug;44(8):1143-1148. doi: 10.1097/PAS.0000000000001469. Am J Surg Pathol. 2020. PMID: 32205484
-
Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma.Hum Pathol. 2023 Nov;141:64-68. doi: 10.1016/j.humpath.2023.09.006. Epub 2023 Sep 28. Hum Pathol. 2023. PMID: 37776956
-
Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.Hum Pathol. 2020 Jun;100:10-14. doi: 10.1016/j.humpath.2020.04.005. Epub 2020 Apr 22. Hum Pathol. 2020. PMID: 32333920
-
New developments in mesothelial pathology.Histopathology. 2024 Jan;84(1):136-152. doi: 10.1111/his.15007. Epub 2023 Sep 11. Histopathology. 2024. PMID: 37694811 Review.
Cited by
-
Mesothelioma: morphologic and immunohistochemical findings.Pathologie (Heidelb). 2024 Sep;45(5):309-315. doi: 10.1007/s00292-024-01317-6. Epub 2024 Apr 3. Pathologie (Heidelb). 2024. PMID: 38568257 Review. English.
-
Role of HEG1 and Claudin-4 Immunohistochemistry in the Differential Diagnosis of Lung Adenocarcinoma from Malignant Mesothelioma in Pleural Effusion Cytology.Turk Patoloji Derg. 2025;41(2):42-50. doi: 10.5146/tjpath.2025.13801. Turk Patoloji Derg. 2025. PMID: 40091315 Free PMC article.
-
Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma.Cancers (Basel). 2025 Feb 1;17(3):481. doi: 10.3390/cancers17030481. Cancers (Basel). 2025. PMID: 39941848 Free PMC article. Review.
-
Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer.Diagnostics (Basel). 2023 Sep 27;13(19):3067. doi: 10.3390/diagnostics13193067. Diagnostics (Basel). 2023. PMID: 37835810 Free PMC article.
-
BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.J Pers Med. 2024 Apr 8;14(4):394. doi: 10.3390/jpm14040394. J Pers Med. 2024. PMID: 38673021 Free PMC article. Review.
References
-
- WHO Classification of Tumors Editorial Board. Thoracic Tumors. Lyon: International Agency for Research on Cancer, 2021; 193-203.
-
- Husain AN, Colby TV, Ordóñez NG et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch. Pathol. Lab. Med. 2018; 142; 89-108.
-
- Facchetti F, Lonardi S, Gentili F et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch. 2007; 451; 669-680.
-
- Ordóñez NG. Value of claudin-4 immunostaining in the diagnosis of mesothelioma. Am. J. Clin. Pathol. 2013; 139; 611-619.
-
- Kleaveland B, Zheng X, Liu JJ et al. Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. Nat. Med. 2009; 15; 169-176.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical